Ekuinas completed the acquisition of a 80% stake in Symbiotica.

Ekuinas, a private equity fund management company, completed the acquisition of a 80% stake in Symbiotica, a pharma ingredients producer. Financial terms were not disclosed. “Having achieved progressive and consistent growth over the past two decades, and being a well-regulated and certified API supplier, Symbiotica, as one of the largest API manufacturers in SEA, is well-positioned to take advantage of the macro trends driving this sector’s future growth," Datuk Syed Yasir Arafat Syed Abd Kadir, Ekuinas CEO.